CLAIMS

1. Use of a therapeutic agent and an intracellular permeation enhancing agent, in the manufacture of a medicament for the therapeutic treatment of cancer in a subject, wherein the therapeutic agent comprises a platinum agent, a vinca alkaloid agent, or a combination thereof, wherein the intracellular permeation enhancing agent is selected from the group consisting of 6-Oxo-6-phenylhexanoic acid, 8-Cyclohexyl-8-oxooctanoic acid, N-(8[2-hydroxybenzoyl]amino)octanoic acid, and a functionally effective salt thereof, wherein the intracellular permeation enhancing agent facilitates the intracellular transport of the therapeutic agent across an intact cell membrane of the tumor and does not have therapeutic activity and wherein the medicament is to be administered intratumorally as an aqueous solution.

2. The use of claim 1, wherein the intracellular permeation agent increases the therapeutic effectiveness of the therapeutic agent and the subject is a mammal selected from the group consisting of a dog, cat, horse, cow, sheep, goat, pig, mouse, rat, guinea pig, monkey and a human.

3. The use of claim 1, wherein the cancer is one or more tumors selected from the group consisting of a solid tumor, a carcinoma and a sarcoma.

4. The use of claim 3, wherein the solid tumor, carcinoma, or sarcoma is of the skin, bone, muscle, breast, oral cavity, colon, organ, kidney, liver, lung, gallbladder, pancreas, brain, esophagus, bladder, large intestine, small intestine, spleen, stomach, prostate, testes, ovaries, cervix, rectum, or uterus.

5. The use of claim 3, wherein the one or more tumors have metastasized.

6. The use of claim 3, wherein the medicament reduces the growth rate of the one or more tumors, shrinks the one or more tumors, eradicates the one or more tumors, or prevents new

tumors.

7. The use of claim 3, wherein the medicament prevents tumor metastasis.

8. The use of claim 1, wherein the therapeutic agent, the intracellular permeation enhancing agent, or both selected based on the volume and type of the tumor.

9. The use of claim 1, wherein the therapeutic agent, the intracellular permeation enhancing agent, or both is suitable for administration on a first day and further is suitable for administration on one or more subsequent days.

10. The use of claim 9, wherein the first day and the one or more subsequent days are separated by between about 1 day and about 3 weeks.

11. The use of claim 9, wherein the therapeutic agent and the intracellular permeation enhancing agent are suitable for coadministration in a ratio of about 1:2, 1:4, 1:10, 1:20, 1:25, 1:50, 1:100, or 1:200 (weight ratio of therapeutic agent:intracellular permeation enhancing agent).

12. The use of claim 9, wherein the intracellular permeation enhancing agent is suitable for administration at a concentration of between about 0.5 mgs per ml of dosing solution and about 50 mgs per ml.

13. The use of claim 9, wherein the intracellular permeation enhancing agent is suitable for administration at a concentration of between about 10 mgs per ml and about 30 mgs per ml of dosing solution.

14. The use of claim 1, wherein the therapeutic agent and the intracellular permeation enhancing agent is suitable for simultaneous administration in a single medicament or is suitable for simultaneous administration in separate medicaments.

15. The use of claim 1, wherein the intracellular permeation enhancing agent is suitable for administration before the therapeutic agent.

16. Use of an aqueous formulation including a therapeutically effective amount of a therapeutic agent and an intracellular permeation enhancing agent, in the manufacture of an intratumoral medicament for the therapeutic treatment of cancer in a subject, wherein the medicament comprises a therapeutic agent selected from cisplatin, vinblastine, or a combination thereof and an intracellular permeation enhancing agent selected from 6-oxo-6 phenylhexanoic acid, 8-Cyclohexyl-8-oxooctanoic acid, N-(8[2-hydroxybenzoyl]amino)octanoic acid, a functionally effective salt of the foregoing, or a combination thereof.

17. The use of claim 16, wherein the formulation comprises cisplatin with N-(8[2-hydroxybenzoyl]amino)octanoic acid.

18. The use of claim 17, wherein the formulation comprises about 0.5 mg/ml of cisplatin with about 10 mg/ml of N-(8[2-hydroxybenzoyl]amino)octanoic acid.

19. The Use of claim 16, wherein the formulation comprises cisplatin and vinblastine with N-(8[2-hydroxybenzoyl]amino)octanoic acid.